Cristiane B Dias1, Patrícia Malafronte2, Jin Lee3, Aline Resende2, Lectícia Jorge2, Cilene C Pinheiro2, Denise Malheiros3, Viktoria Woronik2. 1. Nephrology Department, University of São Paulo School of Medicine Hospital das Clínicas, Rua Dr. Ovídio Pires de Campos, 225, Cerqueira César, São Paulo, SP, 05403-010, Brazil. cristianebitencourt@uol.com.br. 2. Nephrology Department, University of São Paulo School of Medicine Hospital das Clínicas, Rua Dr. Ovídio Pires de Campos, 225, Cerqueira César, São Paulo, SP, 05403-010, Brazil. 3. Department of Pathology, University of São Paulo School of Medicine Hospital das Clínicas, São Paulo, Brazil.
Abstract
INTRODUCTION: Renal histology of proliferative lupus nephritis (LN) shows increased macrophage infiltration, but its association with renal outcome is a matter of debate. Here, we investigate the potential relationship that macrophage expression has with renal prognosis in patients with proliferative LN. METHODS: Fifty patients newly diagnosed with proliferative LN were followed for a median of 8 years. Laboratory testing was conducted at diagnosis, after induction therapy and at the final follow-up evaluation. Renal biopsies were obtained at diagnosis and underwent immunohistochemical analysis with anti-CD68 and monocyte chemoattractant protein 1 monoclonal antibodies. Patients were stratified at final follow-up evaluation into glomerular filtration rate (GFR) >60 ml/min/1.73 m2 (non-progressor group; n = 24) and GFR ≤60 ml/min/1.73 m2 (progressor group; n = 26). All patients were treated with prednisone and six pulses of cyclophosphamide on induction therapy. Conventional maintenance therapy was administered in both groups. RESULTS: Compared to progressors, the non-progressor group showed a lower chronicity index (p = 0.01) and fewer CD68-positive cells in the renal tubules (p = 0.01) and particularly in the renal interstitium (p = 0.0003). Baseline and final serum creatinine correlated positively with the chronicity index (r = 0.3, p = 0.01 and r = 0.3, p = 0.04, respectively), and final serum creatinine correlated positively with interstitial expression of CD68 (r = 0.4, p = 0.0006). CONCLUSION: Renal expression of CD68 and the chronicity index are associated with progression to chronic kidney disease in patients with proliferative LN.
INTRODUCTION: Renal histology of proliferative lupus nephritis (LN) shows increased macrophage infiltration, but its association with renal outcome is a matter of debate. Here, we investigate the potential relationship that macrophage expression has with renal prognosis in patients with proliferative LN. METHODS: Fifty patients newly diagnosed with proliferative LN were followed for a median of 8 years. Laboratory testing was conducted at diagnosis, after induction therapy and at the final follow-up evaluation. Renal biopsies were obtained at diagnosis and underwent immunohistochemical analysis with anti-CD68 and monocyte chemoattractant protein 1 monoclonal antibodies. Patients were stratified at final follow-up evaluation into glomerular filtration rate (GFR) >60 ml/min/1.73 m2 (non-progressor group; n = 24) and GFR ≤60 ml/min/1.73 m2 (progressor group; n = 26). All patients were treated with prednisone and six pulses of cyclophosphamide on induction therapy. Conventional maintenance therapy was administered in both groups. RESULTS: Compared to progressors, the non-progressor group showed a lower chronicity index (p = 0.01) and fewer CD68-positive cells in the renal tubules (p = 0.01) and particularly in the renal interstitium (p = 0.0003). Baseline and final serum creatinine correlated positively with the chronicity index (r = 0.3, p = 0.01 and r = 0.3, p = 0.04, respectively), and final serum creatinine correlated positively with interstitial expression of CD68 (r = 0.4, p = 0.0006). CONCLUSION: Renal expression of CD68 and the chronicity index are associated with progression to chronic kidney disease in patients with proliferative LN.
Authors: Lena Schiffer; Ramalingam Bethunaickan; Meera Ramanujam; Weiqing Huang; Mario Schiffer; Haiou Tao; Michael P Madaio; Michael M Madaio; Erwin P Bottinger; Anne Davidson Journal: J Immunol Date: 2008-02-01 Impact factor: 5.422
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Elena Sánchez; Astrid Rasmussen; Laura Riba; Eduardo Acevedo-Vasquez; Jennifer A Kelly; Carl D Langefeld; Adrianne H Williams; Julie T Ziegler; Mary E Comeau; Miranda C Marion; Ignacio García-De La Torre; Marco A Maradiaga-Ceceña; Mario H Cardiel; Jorge A Esquivel-Valerio; Jacqueline Rodriguez-Amado; José Francisco Moctezuma; Pedro Miranda; Carlos E Perandones; Cecilia Castel; Hugo A Laborde; Paula Alba; Jorge L Musuruana; I Annelise Goecke; Juan-Manuel Anaya; Kenneth M Kaufman; Adam Adler; Stuart B Glenn; Elizabeth E Brown; Graciela S Alarcón; Robert P Kimberly; Jeffrey C Edberg; Luis M Vilá; Lindsey A Criswell; Gary S Gilkeson; Timothy B Niewold; Javier Martín; Timothy J Vyse; Susan A Boackle; Rosalind Ramsey-Goldman; R Hal Scofield; Michelle Petri; Joan T Merrill; John D Reveille; Betty P Tsao; Lorena Orozco; Vicente Baca; Kathy L Moser; Patrick M Gaffney; Judith A James; John B Harley; Teresa Tusié-Luna; Bernardo A Pons-Estel; Chaim O Jacob; Marta E Alarcón-Riquelme Journal: Arthritis Rheum Date: 2012-11
Authors: Elena Gonzalo; Oscar Toldos; María P Martínez-Vidal; María C Ordoñez; Begoña Santiago; Antonio Fernández-Nebro; Estíbaliz Loza; Isabel García; Myriam León; José L Pablos; María Galindo Journal: Arthritis Res Ther Date: 2012-05-28 Impact factor: 5.156
Authors: Vinícius Sardão Colares; Silvia Maria de Oliveira Titan; Alexandre da Costa Pereira; Patrícia Malafronte; Mari M Cardena; Sidney Santos; Paulo C Santos; Cíntia Fridman; Rui Toledo Barros; Viktória Woronik Journal: PLoS One Date: 2014-03-21 Impact factor: 3.240